-
2023 June Ep3: Sotagliflozin (dual SGLT1 and SGLT2 inhibitor) Approval
- 2023/06/30
- 再生時間： 6 分
- ポッドキャスト
-
サマリー
あらすじ・解説
In this episode, we will review the dual SGLT1 and SGLT2 inhibitor, sotagliflozin, joining others with an approval for the treatment of heart failure.
Each month, APhA will release five, 5-minute podcast episodes offering a fresh dose of education highlights, practice pearls, and insights to inform your pharmacy practice and advance patient care. Listen to new episodes at your convenience! Both members and nonmembers can log into their APhA pharmacist.com Learning Library account to successfully complete a short assessment at the end of each month to earn 0.5 hours of CE credits (.05 CEU).
The first inaugural six months are free! Tune in now on our website or subscribe via Google, Spotify, or Apple Podcasts.
Disclaimer: The content is intended for informational purposes only and should not be considered or taken as medical advice. The views and opinions expressed in this program are those of the speakers and do not necessarily reflect the opinions or positions of any entities they represent or its employees.